On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Despite recent challenges, Illumina rebounds with strong preliminary Q4 results, led by the successful NovaSeq X launch and strategic alliances, positioning itself as a key player in the genomics ...

Firm asks stockholders not to tender shares and to support Illumina at its annual meeting. Roche’s proposed acquisition of Illumina is continuing to play out just like any hostile takeover of a market ...

Examples of both strength and sluggishness are likely in the gene-sequencing pioneer's upcoming financial update. The company announces its full-year 2018 and fourth-quarter financial results after ...

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...

CAMBRIDGE, England--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities ...

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $122.00. The company’s shares closed yesterday at ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) yesterday and set a price target of $242.00. The company’s shares closed last Friday at $104.38.

Giant Cell Arteritis (GCA) is the most common vasculitis affecting the elderly. Archived formalin-fixed paraffin-embedded (FFPE) temporal artery biopsy (TAB) specimens potentially represent a valuable ...